Search results for: Isobel Firth
Filter search results
New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
25 May 2023
…responsibility of the authors. Related Research Firth, I., Pan, J., Towse, A., Steuten, L., 2023. A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance. OHE Contract Research…
Rare Disease Day 2024: Why Do We Care About Rare?
29 February 2024
…Payment Models for Multi-Indication Therapies. Office of Health Economics; 2021. Accessed December 14, 2021. https://www.ohe.org/publications/payment-models-multi-indication-therapies Henderson N, Firth I, Errea M, Skedgel C, Jofre-Bonet M. A Case Study Analysis: Challenges…
The 2020 OHE Annual Lecture Explores the Question: How Should the World Pay for a COVID-19 Vaccine?
25 June 2020
…drugs. Citation Towse, A. Firth, I. (2020) How should the world pay for a COVID-19 vaccine? Draft paper to accompany the 2020 OHE Annual Lecture. Office of Health Economics….
Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
16 January 2024
…PMCID: PMC8234425. Årdal et al., 2023. A Pan-EU/EEA Pull Incentive for Antimicrobial Innovation and Access. DRIVE-AB Policy Brief. Available at: https://drive-ab.eu/news/drive-ab-policy-brief-a-pan-eu-eea-pull-incentive-for-antimicrobial-innovation-and-access/ Brassel S., Firth I., Oliver E., Hampson, G., Towse A….
Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
1 June 2021
…place. Acknowledgement: This report was commissioned by Novartis Gene Therapies. Citation Firth I., Schirrmacher H., Hampson G., Towse A. Key considerations for early access schemes for one-time therapies., London: Office…
Estimating the Impact of U.S. Drug Price-setting Policies on Innovation Is Challenging, Even for the Congressional Budget Office
22 June 2022
…Related Research Hitch, J., Firth, I., Hampson, G., Jofre-Bonet, M., Garau, M., Garrison, L. and Cookson, G. (2021) The Lower Drug Costs Now Act and Pharmaceutical Innovation. OHE Consulting Report….
Cost-Effectiveness Thresholds and Expert Elicitation: a Bridge Too Far?
29 April 2021
…Sampson, C., Firth, I. and Towse, A., 2021. Health Opportunity Costs and Expert Elicitation: A Comment on Soares et al. Medical Decision Making, 41(3), pp.255–257. 10.1177/0272989X20987211. Barnsley, P., Towse, A.,…
The Broader Value of Existing Vaccines in the Fight Against COVID-19: Beware of Tunnel Vision
8 October 2020
…Fight COVID-19? ? OHE Commentary, London: Office of Health Economics. Available at: https://www.ohe.org/news/economics-innovation-times-pandemic-how-incentivise-development-supply-and-continuous Towse, A. Firth, I. (2020) How should the world pay for a COVID-19 vaccine? Draft paper to…